Tracer library / [89Zr]vMET1-Fc
[89Zr]vMET1-Fc
Also written as [Zr-89]Zr-vMET1-Fc
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- Shark-derived single-domain VNAR antibody fused to human Fc domain (VNAR-Fc theranostic construct)
- Target / mechanism
- Targets MET receptor tyrosine kinase, internalized by MET-positive cells PMID 41676672
- Clinical application
- PET/CT imaging of MET-altered NSCLC as part of a theranostic pair with [177Lu]Lu-vMET1-Fc for radiotherapy PMID 41676672
- Theranostic pair
- [177Lu]Lu-vMET1-Fc
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [89Zr]vMET1-Fc, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41676672. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41676672: 'High tumor uptake with low background was observed in MET-positive NSCLC xenografts administered [89Zr]Zr-vMET1-Fc.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 41676672.